203 results about "Thalassemia" patented technology

The present invention is directed to the use of immunomodulatory compounds, particularly members of the class of compounds known as IMiDs™, and more specifically the compounds 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione and 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione, to induce the expression of fetal hemoglobin genes, genes essential for erythropoiesis, and genes encoding alpha hemoglobin stabilizing protein, within a population of CD34⁺ cells. These compounds are used to treat hemoglobinopathies such as sickle cell anemia or β-thalassemia, or anemias caused by disease, surgery, accident, or the introduction or ingestion of toxins, poisons or drugs.

This invention relates to test kit and test paper with oligonucleotide probes for diagnosing alpha-thalassemia. The test paper comprises a base, and specific oligonucleotide probes immobilized on the base. The oligonucleotide probes comprise: specific oligonucleotide probes for detecting mutation of alpha-globin gene, specific oligonucleotide probes for detecting deletion of alpha-globin gene, and base sequence complementary with the above sequences. The test kit comprises specific primer for amplifying alpha-globin gene or transcript, and specific oligonucleotide probes for detecting mutation/deletion of alpha-globin gene. The test kit and the test paper have such advantages as low cost, rapid detection, and stable results. The test kit and the test paper can be used in detection of mutation/deletion of alpha-globin gene, and prenatal diagnosis of severe thalassemia (alphaTalpha) caused by point mutation, and do not have error diagnosis.

Disclosed herein are carbonyl compounds of Formula I, II, or III, and others as described herein.

Also disclosed are methods of treating disease, such as cancer, neurological disorders, including polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, autoimmune diseases and cardiovascular conditions, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

The invention discloses a thalassemia gene detection method based on a fluorescence labeling quantitation PCR (Polymerase Chain Reaction) technology, and the detection method mainly comprises the following steps of: firstly designing a general fluorescence labeling primer; then designing an amplification primer aiming at a detection site; when the amplification primer is designed, tailing one primer of an amplification primer pair, wherein the tailing sequence is consistent to the sequence of the general fluorescence labeling primer; when PCR reaction is carried out, mixing a tailed primer group and the general fluorescence labeling primer to realize the fluorescence labeling of an amplification product; and after the PCR reaction is finished, placing PCR products into a sequencer, and confirming the lengths of different PCR products through a series of internal references of known molecular weight of a result by utilizing the Genemapper function of the sequencer to judge the genetype of a detected sample. The detection method disclosed by the invention can realize the detection of different genotypes of alpha thalassemia through a single tube.

The invention discloses a group of probes, a detection kit and a detection method for detecting thalassemia gene point mutation based on a liquid chip of locked nucleic acid sensibilization. Due to the characteristics that locked nucleic acid can flexibly modify probes, probes for detecting thalassemia gene point mutation are designed; these probes are respectively coupled to different numbers of microspheres; a specific primer disclosed by the invention is designed to amplify mutation sites, so as to obtain a PCR product; the PCR product is hybridized with the microspheres coupled to the probes; fluorescence labeling is carried out by using a fluorescence labeling reagent; and finally detection on the mutation sites is carried out through a liquid chip detector. The probes based on LNA sensibilization are shortened in comparison with a conventional probe, and still can keep relatively high Tm values; so that the hybridization signal ratio of completely matched probes and mismatched probes is improved to over four times from below twice in the past, thus the probes are easy to distinguish.

The present invention provides methods for increasing endogenous globin expression in a subject, specifically γ-globin expression. The invention also provides compounds and medicaments for use in the methods. The methods are particularly useful for increasing fetal hemoglobin production in a subject, and can be used to treat various disorders, e.g., β thalassemia and sickle cell disease.

The invention relates to diagnostic reagent of mediterranean anemia, in particular to a nucleic acid membrane strip and kit for alpha and beta mediterranean anemia gene detection. The technical scheme is that the nucleic acid membrane strip for alpha and beta mediterranean anemia gene detection comprises a substrate and a specific oligonucleotide probe fixed on the substrate, wherein the specific oligonucleotide probe comprises 6 normal alpha-mediterranean anemia (3 deletion types and 3 mutant types) probes and 17 mutant type beta-mediterranean anemia probes. By means of the nucleic acid membrane strip and the kit, deflection type alpha-mediterranean anemia, non-deflection type alpha-mediterranean anemia and beta-mediterranean anemia can be detected in one step simultaneously. Compared with the existing like technology, 2 unreported beta-mediterranean anemia (-30 and -32) and 1 unreported non-deflection type alpha-mediterranean anemia (alpha WS alpha) are detected simultaneously, occurrence rate of the three mediterranean anemia in China is not low, the risk of leak detection in poor areas can be greatly increased without detection, and severe burden can be brought to families and the society.

The invention belongs to the field of biochemistry, and provides a fluorescent quantitative polymerase chain reaction (PCR) kit for detecting alpha-globin gene deletion. The kit consists of a pair of specific amplified xi globin primers, a pair of specific amplified alpha1 globin primers, a pair of specific amplified alpha2 globin primers, a pair of specific amplified beta-Actin gene primers, a fluorescent probe for specifically detecting xi globin, a fluorescent probe for specifically detecting alpha1 globin, a fluorescent probe for specifically detecting alpha2 globin, a fluorescent probe for specifically detecting beta-Actin genes, a DNA polymerase and the like. The kit has good sensitivity and accuracy for detecting depletion alpha-thalassemia, has good repeatability and stability, and is totally suitable for clinical detection of alpha-thalassemia.

The invention discloses a method for detecting a fetal thalassemia pathogenic gene, which comprises the following steps of: (1) screening SNP sites, wherein the SNP sites are used for designing a primer pool of the thalassemia gene in an amplification genome and for capturing the probe of the thalassemia gene of the free DNA in the plasma of a pregnant woman; (2) extracting the free DNA in the plasma of the pregnant woman and the whole blood genomic DNA of the father, the mother and a born sibling and constructing a corresponding DNA library, and carrying out template preparation and enrichment; (3) sequencing the free DNA and the whole blood genomic DNA library in step (2); (4) constructing the haploid genotype of the SNP sites on the thalassemia gene, combining the sequencing informationof the free DNA and the whole blood genomic DNA library, analyzing the genetic condition of the parent source and the genetic condition of the parent source, so as to determine the corresponding genotype of the SNP sites of the fetal. According to the method, target area capture and high-throughput sequencing technology are used, so that the noninvasive antepartum detection of the thalassemia isrealized; the required sample amount is small; on the basis of detecting the mutation of the parent source, the method can realize the detection of the gene mutation of the maternal source of the fetal.

The invention discloses a real-time fluorescence quantitative PCR(Polymerase Chain Reaction) detection kit and related primers for thalassemia genes. The kit comprises more than one pair of the following primers: SEQ ID NO.1 and SEQ ID NO.2 aiming at TATA kits nt-28 (A->G) (-28M), -29 (A->G) (-29M) and CAP-40-43 (AACC) (CAPM) genotypes; SEQ ID NO.3 and SEQ ID NO.4 aiming at CD14-15 (+G) (14-15M), CD17 (A->T) (17M) and the initiation codon mutant ATG->AGG(IntM) genotypes; SEQ ID NO.5 and SEQ ID NO.6 aiming at CD26 (G->A)(betaEM) CDs27-28+C(27-28M), IVS1-1(G->T)(IVS1-1M), IVS1-5(G->C)(IVS1-5M) genotypes; SEQ ID NO.7 and SEQ ID NO.8 aiming at CDs41-42-TCTT (41-42M), CD43G->T(43M), 41-42M/41-42M genotypes; SEQ ID NO.9 and SEQ ID NO.10 aiming at CD71-72(+A) (71-72M) genotypes; SEQ ID NO.11 and SEQ ID NO.12 aiming at IVS2-654C->T(654M) and 654M/654M genotypes; and SEQ ID NO.13 and SEQ ID NO.14 aiming at constant spring (CS), Quong Sze (QS) and Westmead (WS) genotypes. The kit has the advantages of good detection specificity and high detection sensitivity.

The invention provides a kit capable of simultaneously detecting 6 deletion type alpha-thalassemia genes (-alpha<3.7>, -alpha<4.2>, --<SEA>, --<THAI>, --<FIL> and -alpha<27.6>) and 6 non-deletion type alpha-thalassemia genes (alpha<CS>alpha, alpha<QS>alpha, alpha<WS>alpha, alpha<13>alpha, alpha<43-44>alpha and alpha<49>alpha).The kit comprises a DNA chip, PCR reaction liquid I and PCR reaction liquid II, wherein the DNA chip comprises a substrate and probes fixed on the substrate.The kit has the advantages that the detection principle of PCR-reverse dot blot is used, the corresponding amplification primers and probes are designed according to the mutated or deleted sites of the genes, the probes are fixed on the DNA chip, and thalassemia is diagnosed through the hybridization of PCR products amplified by the specific primers and the probes fixed on the DNA chip and the interpretation of a signal developing box.

A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia.

This disclosure provides compositions and methods for improving erythrocyte dysfunction or treating a hemoglobinopathy or a thalassemia (e.g., sickle cell disease or β-thalassemia).

The invention discloses a kit for simultaneously detecting thalassemia mutant type and deletion type and application thereof, wherein the kit includes a plurality of amplimer groups for amplifying thalassemia genes; the amplimer groups include primers designed by aiming at alpha globin genes and beta globin gene, and mutant type detecting primers aiming at HBA1 genes, HBA2 genes and HBB genes, anddeletion type detection primers aiming at alpha thalassemia genes -alpha 3.7, -alpha4.2,--SEA,--THAI and beta deletion type SEA-HPFH, sinotype and Taiwantype. Through adopting the kit, the thalassemia mutant type and deletion type can be simultaneously detected, particularly, seven common deletion types and more than 300 mutant types can be simultaneously detected, and novel mutant types can be found out; furthermore, the cost is low, and the kit is much superior to the conventional thalassemia detection kit.

An sgRNA editing HBB-28 mutation site based on CRISPR/Cas9 technology is disclosed, the nucleotide sequence of which is shown in SEQ ID NO.1 or SEQ ID NO.2. The invention also provides a vector associated therewith, a cell, a gene editing kit and an application thereof, in particular a method for editing the HBB-28 mutation site based on the CRISPR/Cas9 technology, comprising constructing a CRISPR/Cas9 expression vector use sgRNA having a nucleotide sequence represented by SEQ ID NO.1 or SEQ ID NO.2. The invention can specifically induce HBB-28 Traceless modification of gene mutation sites inthalassemia can selectively introduce monoallelic and biallelic sequence changes with high efficiency and precision, which greatly promotes the precise repair of thalassemia.

An sgRNA editing 41/42 deletion mutation site of beta globin gene edit based on CRISPR/Cas9 technology is provided, and that nucleotide sequence thereof is shown as SEQ ID NO.1. The invention also provides a carrier associated therewith, a cell, a gene edit kit and application thereof, in particular a method for editing the 41/42 deletion mutation site of the beta globin gene based on the CRISPR/Cas9 technology, comprising constructing a CRISPR/Cas9 expression vector using sgRNA having a nucleotide sequence as shown in SEQ ID NO:1. The invention can specifically induce the traceless directional modification of gene mutation sites in beta globin gene 41/42 thalassemia, can selectively introduce single allele and double allele sequence changes with high efficiency and precision, and greatlypromotes the improvement of precise repair.

The invention provides a bar code magnetic bead liquid chip detection kit for a thalassemia gene. The detection kit comprises a PCR reagent for amplifying the thalassemia gene and a hybridization reagent for detecting the thalassemia gene; the hybridization reagent comprises a liquid chip; the liquid chip comprises a bar code magnetic bead coupled with a specificity hybridization probe, a blank bar code magnetic bead, a dissociative hybridization positive inverted-sequence probe and a hybridization buffer solution. The detection kit is simple to operate, quick in reaction, high in flux, and digitized.

The invention provides a kit capable of detecting four deletion alpha-thalassemia genes (-alpha<3.7>, -alpha<4.2>, --<SEA> and --<THAI>) and three non-deletion alpha-thalassemia genes (alpha<CS>alpha, alpha<QS>alpha and alpha<WS>alpha) at the same time.The kit comprises a DNA chip, a PCR solution I and a PCR solution II.The DNA chip comprises a substrate and probes fixed to the substrate.The kit has the advantages that based on the PCR-reversal point hybridization detecting principle, corresponding amplification primers and probes are designed according to the mutation or deletion loci of genotypes, biotin is used for labeling the primers, amidogen is used for labeling the probes, the DNA chip (nylon membrane) is adopted as a substrate, the probes are fixed to the nylon membrane, and PCR products amplified by the specific primers and the probes fixed to the DNA chip are subjected to hybridization and signal developing box interpretation to diagnose thalassemia.

The embodiments herein provide a powdered composition of natural substances for controlling deficiencies in polypeptide alpha and beta hemoglobin chains and a diet plan for treating thalassemia patient. The composition comprises passargad powder, pars powder, purgative material, fumigation material, snuffing material, vinegar syrup and parsomash powder. The passargad powder is a stomach tonic and acts as anti-parasitic, anti-diarrheal, anti-dysentery, anti-bloating and anti-heartburn agents. The pars powder comprises sprouted grains for providing nutrition to cells. The purgative material is body purifier or detoxification agent and helps in motion and bowl movement. The vapor/fumigation material softens and reduces stickiness of sputum and removes sputum. The snuff helps in sneezing and removal of sputum. The vinegar syrup breaks down fat and removes toxins. The parsomash is an detoxification agent. The composition and dietary plan eliminates the need of bone marrow transplant, blood transfusion and defroxamin in thalassemia patients.

The invention provides a kit and method for detecting mutation of a thalassemia-related gene and a use thereof and relates to the technical field of medical genetics. The kit for detection is used for detecting many types of patients such as people needing premarital checkup, people in gestation, newborns, people in a zone having high incidence of thalassemia and people having thalassemia family heredity history, can realize accurate, comprehensive, visual and simple detection of mutation of a thalassemia-related gene, has a detection mutation range comprising HBA1, HBA2 and HBB genes in the genome and neighbouring zones and has the characteristics of simpleness, accuracy, good repeatability and promotion and use easiness.

The invention discloses a kit for detecting common deletion form alpha-thalassemia and a using method of the kit. The kit comprises a pair of primers capable of performing simultaneous amplification of a signature sequence A1 in an alpha 1 section and a signature sequence A2 in an alpha 2 section in an alpha-globin gene cluster, a pair of primers capable of performing amplification of a --<SEA> genetype in the alpha-globin gene cluster and a pair of primers capable of performing amplification of a --<THAI> genetype in the alpha-globin gene cluster as well as a fluorescence probe for specific detection of the signature sequence A1 in the alpha 1 section, a fluorescence probe for specific detection of the signature sequence A2 in the alpha 2 section, a fluorescence probe for specific detection of a --<SEA> genetype amplicon and a fluorescence probe for specific detection of a --<THAI> genetype amplicon. As for the alpha-thalassemia globin gene deletion detection, the kit provided by the invention has high sensitivity, stability, accuracy and specificity.

The invention discloses a lentiviral vector suitable for gene therapy of thalassemia and sickle anemia. The lentiviral vector comprises a beta globin expression cassette; the expression cassette comprises a micro-locus control area, a gene sequence of a beta globin, a promoter sequence of a flank of the upstream of the gene sequence of the beta globin, and a flanking sequence of the downstream ofthe gene sequence of the beta globin; the micro-locus control area is a micro-control element which is screened out from the locus control area of beta globin 16kb and does not contain an HS1 area. Compared with the prior art, the screened beta globin expression cassette has both efficiency and specificity, and does not cause reduction of lentivirus titer; a screened insulator sequence which comesfrom foamy virus and is only 36 bp does not contain a hidden RNA splicing signal, and has the functions of maintaining gene expression and preventing gene activation in a region where the insulator sequence is located; the lentiviral vector can be used for gene therapy of thalassemia and sickle anemia.

The present invention relates to vectors comprising an alpha -globin locus control region ( alpha LCR) and a gene encoding an erythroid protein. In particular embodiments, a retroviral vector comprising an alpha LCR and a globin gene may be used to treat globin-based genetic disorders, including sickle cell anemia and beta -thalassemia.

The invention relates to a method for determining a fetus alpha thalassemia gene haplotype. The method comprises the following steps: establishing a third-generation sequencing library according to ablood sample, wherein the blood sample is collected from blood samples of the father and mother of the fetus; performing the third-generation sequencing for the third-generation sequencing library, and obtaining a third-generation sequencing result; determining a father and mother alpha thalassemia gene haplotype according to the third-generation sequencing result; establishing a second-generationsequencing library according to a detection sample, wherein the detection sample is collected from a peripheral blood sample of a pregnant woman; performing the second-generation sequencing for the second-generation sequencing library, and obtaining a second-generation sequencing result; and determining the fetus alpha thalassemia gene haplotype according to the second-generation sequencing result as well as the father and mother alpha thalassemia gene haplotype.